Ascendis Pharma and Novo Nordisk Sign Collaboration for …
3 days ago · - Collaboration leverages Ascendis’ proprietary TransCon ™ technologies and Novo Nordisk’s expertise in cardiometabolic diseases - Once-monthly GLP-1 receptor agonist will be the collaboration’s lead product candidate. COPENHAGEN, Denmark, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has granted Novo Nordisk A/S an exclusive worldwide ...
Novo Nordisk Commits $285M to Ascendis to Kick Off Alliance …
3 days ago · Novo Nordisk was a pioneer in developing GLP-1 drugs for metabolic disorders, but its products are still mainly once-weekly injections. The Danish pharmaceutical giant is putting up $285 million ...
Novo puts $285m into monthly GLP-1 based on Ascendis tech
2 days ago · Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist. The Danish pharma ...
Novo pens $285M biobucks deal to use Ascendis' tech to create …
3 days ago · Novo Nordisk has signed off on a. In return for granting Novo the license to use the platform for the lead GLP-1 program, Ascendis is in line for up to $285 million in combined upfront ...
Novo inks Ascendis deal to develop long-acting GLP-1, other …
3 days ago · Novo Nordisk is investing further in obesity and metabolic disease, signing a deal to use Ascendis Pharma’s delivery technology to advance a long-acting GLP-1 drug as well as develop products in diabetes and cardiovascular conditions, Ascendis said Monday. Per deal terms, Novo could pay up to $285 million in immediate and milestone-based fees ...
Novo Nordisk GLP-1 Drug Meets Goals of MASH Trial, Setting …
6 days ago · Novo Nordisk also said 62.9% of patients in the Wegovy group achieved resolution of the fatty liver disease with no worsening of liver fibrosis. By comparison, 34.1% of those in the placebo group ...
Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting …
Sep 11, 2024 · Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potenti.
News Details - Novo Nordisk
Jun 4, 2021 · Wegovy™ is the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management for people living with obesity. The approval is based on the results from the STEP phase 3a clinical trial programme.
News Details - Novo Nordisk
Bagsværd, Denmark, 22 May 2023 – Novo Nordisk today announced headline results from OASIS 1, a phase 3a trial in the global OASIS programme. OASIS 1 is a 68-week, efficacy and safety trial comparing once-daily oral semaglutide 50 mg for weight management to placebo in 667 adults with obesity or overweight with one or more comorbidities.
Novo Nordisk signs $285 million deal for a once-monthly Wegovy
8 hours ago · News and analysis on clinical trial services and contract research and development. Novo Nordisk signs $285 million deal for a once-monthly GLP-1 receptor agonist. Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug. Ascendis Pharma has granted Novo Nordisk an exclusive worldwide ...
- Some results have been removed